Maryam Abdollahi, PhD

SCIENTIFIC ADVISOR

With almost a decade of acquired scientific expertise, Maryam Abdollahi has built a distinguished career. As a determined and highly skilled scientific researcher possessing expertise spanning histology, biotechnology and medical research, she has met the challenges of complex research problems. Her success to date has largely been determined by her innate intelligence, deductive problem solving abilities in conjunction with proven aptitude to conduct qualitative and quantitative analysis of retrieved data. Her command of modern methods such as SPSS and GraphPad Prism have proven invaluable aids to achieving desired results. Able to use multidisciplinary approaches, she approaches solutions from an array of possible venues of inquiry, thus yielding consistent quality in findings. Her laboratory acumen is only strengthen by effective communicative and interpersonal abilities, a dedicated work ethic with the flexibility to deal with all contingencies, and, if needed, to be the first to take targeted steps in case of technical and other difficulties.

Complementing an intellect that thrives on inquiry, she is a highly skilled professional in her field. In addition to flow cytometry, cell culture, quantitative real time PCR, Western blot and zymography and electron microscopy, she is skilled in animal surgery and genotyping. Her specific expertise in histology embraces a lengthy background in tissue processing, microtome, sectioning, immunohistochemistry staining and immunofluorescence dual staining.

Maryam is widely published in her field. Her co-authored text, Momordica Charantia Whole Fruit Aqueous Extract: Effects on Histopathological Changes in Non-insulin Dependent Diabetes Mellitus (NIDDM) in a Rat Model in many ways represents a culmination of her work. Currently, several journal articles on the connection between neutrophil activation and diabetes wound healing represent a particular area of interest. Previously published articles have addressed the effects of Momordica Charantia on various diabetic consequences. She has presented her research findings in such international scholarly forums as the International conferences.
In addition, she has received considerable academic recognition including an Australian Postgraduate Award scholarship from The University of Sydney, 2011 as well as an International Postgraduate Research Scholarship to continue dissertation research. In both 2012 and 2013 she was awarded a Postgraduate Research Support Scheme from the University. Now having completed doctoral studies, and started her post-doctoral fellow at the City of Hope.

Upon receipt of a BS in Biology-Botany, Maryam went on to earn a Master of Veterinary Science, Histology and then earned her doctorate from the University of Sydney. Of particular note is the fact that she is from a nation where advancement for women is challenging, and has become a role model for young women both in her country and beyond.

Disclaimer

For Medical Professional Viewing Only

 

Stemell, Inc. does not claim that therapy using StemL products cures or prevents any condition, disease or injury. All statements and opinions provided are for educational and informational purposes only, and we do not diagnose or provide medical or legal advice.

Individuals interested in any cellular or cell-free regenerative medicine therapy are urged to review all pertinent information and do their own research and due diligence before choosing to participate in any therapies. Please consult with your physician for further information and be sure to discuss any potential risks.

Please understand that Stemell, Inc. is a supplier only. Stemell, Inc. is not a sponsor, and Stemell, Inc. is not claiming to cure or treat any disorder or condition.

This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.

The FDA has stated:
Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194655.htm

This site is not intended for consumers.
If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.

“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else. If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm286155.htm

Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.